Inclusion Criteria:~* Subjects with all cause dementia and probable Alzheimer's disease at enrollment and who
completed participation in one of the following three TauRx studies (inclusive of the 4-week post-treatment
follow-up visit): TRx-237-005, TRx-237-008, or TRx-237-015.~* Subjects with a diagnosis of probable bvFTD at
enrollment and who completed participation in TauRx study TRx-237-007 through Visit 9 (Week 52).~* Females, if
of child-bearing potential, must practice true abstinence or continue to use adequate contraception and agree
to maintain this throughout the study~* Subject, and/or, in the case of reduced decision-making capacity,
legally acceptable representative(s) consistent with national law and ethics approval is/are able to read,
understand, and provide written informed consent~* Has an identified adult caregiver who is willing to provide
written informed consent for his/her own participation; is able to read, understand, and speak the designated
language at the study site; either lives with the subject or sees the subject for ≥1 hour/day ≥3 days/week;
agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug~*
Able to comply with the study procedures~
